Search results
Results From The WOW.Com Content Network
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Since August 2012, the third-generation cephalosporin, ceftriaxone, is the only recommended treatment for gonorrhea in the United States (in addition to azithromycin or doxycycline for concurrent Chlamydia treatment). Cefixime is no longer recommended as a first-line treatment due to evidence of decreasing susceptibility. [30] Ceftriaxone ...
As of 2010, the recommended treatment is a single 250 mg intramuscular injection of ceftriaxone, sometimes in combination with azithromycin or doxycycline. [3] [4] However, certain strains of N. gonorrhoeae can be resistant to antibiotics that are normally used to treat it.
Ceftriaxone (IV and IM, not orally, effective also for syphilis and uncomplicated gonorrhea) Rocephin: Cephalosporins (Fourth generation) Cefepime: Maxipime: Covers pseudomonal infections. Gastrointestinal upset and diarrhea; Nausea (if alcohol taken concurrently) Allergic reactions
For ceftriaxone, the color of solutions can range from light yellow to amber, depending on the length of storage, concentration, and diluent used. [30] [31] A study found that meropenem concentrations dropped to 90% of the initial concentration at 7.4 hours at 22°C and 5.7 hours at 33°C, indicating degradation over time. [29]
Ceftaroline fosamil / s ɛ f ˈ t ær oʊ l iː n /, brand name Teflaro in the US and Zinforo in Europe, [1] [2] is a cephalosporin antibiotic with anti-MRSA activity. [3] Ceftaroline fosamil is a prodrug of ceftaroline.
The term injection encompasses intravenous (IV), intramuscular (IM), subcutaneous (SC) and intradermal (ID) administration. [35] Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often occurring in 15–30 seconds for IV, 10–20 minutes for IM and 15–30 minutes for SC. [36]
Cefotaxime is administered by intramuscular injection or intravenous infusion. As cefotaxime is metabolized to both active and inactive metabolites by the liver and largely excreted in the urine, dose adjustments may be appropriate in people with renal or hepatic impairment. [8] [18] [19]